Similar User
@all_isee
@masa04966040
@YaleGreenChem
@cmc_lab
@iiiitoooo
@sony_satouchi
@LarrosaGroup
@johnpoverington
@dipimp
@TakahashiKH
@HRPTV5C
🚨 Warning on Sotorasib Treatment for Advanced Lung Cancer🫁 Sotorasib, the first RAS inhibitor approved for KRASG12C-mutated NSCLC, showed improvements in progression-free survival (PFS) in the CodeBreaK 200 trial. However, in October 2023, the FDA rejected its regular…
So finally common sense prevailed. Company has decided to withdraw the BLA for Datopotamab Deruxtecan based upon Tropion Lung 01 trial. That was a negative trial which was presented and propagated as Positive trial ( read the JCO publication below ). Let's look forward to new…
I don't know about you but I will call this study as Negative. Datopotamab deruxtecan vs Docetaxel for advanced NSCLC. Tropion Lung01 . Dual primary end points -PFS and OS. PFS In non Squamous histology is better- 3.7 vs 4.4 , it is detrimental in Squamous histology- 2.8 vs…
ひゃーすごい。KRASワクチンELI-002の第1相AMPLIFY-201試験、KRAS G12DやG12Rで完全奏効を連発している。KRAS変異ペプチドを抗原認識させるらしい。これ、G12C以外のKRASも本当に克服される時代が来そうだゾ！／Nat Med nature.com/articles/s4159…
A lot to digest here! Pan-cancer ADC targets over the past two decades nature.com/articles/s4141… #ADC #ADCtargets #ADChistory
ADC remains 🔥🔥🔥 With $ABBV's ~$10B acquisition of $IMGN today, the # of independent late-stage ADC players thins again (to go along with Pfizer / SeaGen and Merck / Daiichi). At this point, the biggest names are accounted for. ~$2B in WW consensus peak sales for Elahere…
The ADC space is blowing up: • >$125B in partnerships and M&A since 2019, including Pfizer's $43B acquisition of $SGEN and a record $5.5B upfront deal ($MRK / Daiichi) this year • Hundreds of assets across thousands of trials • 8 approvals in the last 5 years (13 total) I…
PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer: Cell Chemical Biology cell.com/cell-chemical-…
Serina has licenced their POZ polymer technology to Pfizer 🤝. The delivery platform hopes to improve upon the limitations of other technologies like PEG 🔗 Read the full article here: hubs.la/Q029yjyP0
うお、まじか。PARP阻害剤とCDK4/6阻害剤を併用することで、IFNβを介した免疫状態と協調して（one-twoパンチ！？）細胞増殖を抑制するという野心的な研究。しかもPARPiとCDK4/6iなので乳腺の話と思いきや大腸癌細胞での研究らしい。微小環境むずかしい。 ／Cancer Sci onlinelibrary.wiley.com/doi/full/10.11…
内訳は下記のようです 小児医薬品開発ネットワーク支援事業 2500万円 小児医薬品開発支援体制強化事業 4800万円 医療系ベンチャー海外投資獲得支援事業 1.2億円 シーズ実用化可能性調査支援事業 5000万円 nk.jiho.jp/article/185345
Ionis/Denaliより、IV投与-BBB突破型 Antibody-ASO conjugatesの報告。 Denail社のOTV技術を採用。従来のトランスフェリン受容体 (TfR) 抗体-コンジュゲートより、マウス脳で高いノックダウン活性を確認。 naked-ASOのサルIT投与と比較しても、分布・薬効・安全性の面で改善。 biorxiv.org/content/10.110…
Just published FALURA 2‼️ @NEJM Congratulations @dplanchard & all investigators. Well deserve. nejm.org/doi/pdf/10.105… #LCSM #WCLC23 @EGFRResisters @OncoAlert
For more on overcoming resistance to #KRAS inhibitors, check out this related @CR_AACR article from @derlabunc: TEAD Inhibition Overcomes YAP1/TAZ-driven Primary and Acquired Resistance to KRASG12C Inhibitors aacrjournals.org/cancerres/arti…
Interested in targeting #KRAS? Be sure to read this article online now in @CR_AACR: Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy @DrBenNeel @sumanmukhpdhyay aacrjournals.org/cancerres/arti…
Great article about ADCs by @PTarantinoMD It is concluded that several issues have been raised and, if addressed appropriately, will lead to clinical benefits for patients with a variety of cancer types over the next decade. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert
New @biorxivpreprint from our lab by @Qian37774492 on a covalent 14-3-3 molecular glue with the transcription factors YAP and TAZ and using this glue as a 14-3-3 recruiter to sequester nuclear neo-substrates into the cytosol! Thanks to #AppleTreePartners & @themarkfdn…
From Nathanael Gray’s lab: Chemical Specification of E3 Ubiquitin Ligase Engagement by Cysteine-Reactive Chemistry—discovering electrophilic handles for protac applications that operate through covalent targeting of dcaf16 or dcaf11! pubs.acs.org/doi/10.1021/ja…
5/19 #TumorBoardTuesday 👨🏽🏫Mini Tweetorial 2👨🏽🏫 📌Comprehensive Genomic Profiling of primary & metastatic prostate tumors 📍most frequently altered TP53 (43.5%) PTEN (32.2%) TMPRSS2-ERG (31.2%) AR (22.5%) MYC (12.3%) BRCA2 (9.8%) RB1 (9.7%) 📚@EthanSokol ascopubs.org/doi/10.1200/PO…
社会保険とりわけ医療保険制度の説明をするようになってから、後期高齢者医療制度に他の保険制度（組合健保や協会けんぽ、国保）から巨額の支援金を出しているのはおかしいとの声をいただくことが増えた。…
アカデミアでの基礎研究から応用、社会実装まで骨太でガッツリ戦ってる高橋先生ならではの意見。 ダメになっている、はもはや論点でないので、どう変えていくか。 呼びかけ、啓蒙では弱い。 やっぱりぶち抜けた大学発ベンチャーの成功例を作るしかない、か。 その時はもう近いかもしれない。
久しぶりに、海外のアカデミアのミーティングに次々参加して、これまで書こうか迷っていたことをやはり書いておこうと思います。…
久しぶりに、海外のアカデミアのミーティングに次々参加して、これまで書こうか迷っていたことをやはり書いておこうと思います。…
United States Trends
- 1. Mike 1,81 Mn posts
- 2. #Arcane 169 B posts
- 3. Serrano 243 B posts
- 4. Jayce 28,5 B posts
- 5. Vander 8.229 posts
- 6. Canelo 17,2 B posts
- 7. MADDIE 13,5 B posts
- 8. #NetflixFight 74,8 B posts
- 9. Father Time 10,8 B posts
- 10. Logan 80,2 B posts
- 11. #netflixcrash 16,7 B posts
- 12. Jinx 83,8 B posts
- 13. He's 58 28,4 B posts
- 14. Boxing 309 B posts
- 15. ROBBED 101 B posts
- 16. Rosie Perez 15,2 B posts
- 17. Shaq 16,6 B posts
- 18. #buffering 11,2 B posts
- 19. Tori Kelly 5.412 posts
- 20. Roy Jones 7.319 posts
Who to follow
Something went wrong.
Something went wrong.